Related Experiment Video

Updated: Aug 3, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Recent advances in JAK3 kinase inhibitors

E A Sudbeck1, F M Uckun

  • 1Parker Hughes Cancer Center, Hughes Institute, 2665 Long Lake Road, Suite 330, St Paul, MN 55113, USA. Fatih_Uckun@mercury.ih.org

Idrugs : the Investigational Drugs Journal
|August 25, 2005
PubMed

Insights

WHI-P131, a JAK3 inhibitor, shows promise for treating childhood acute lymphoblastic leukemia (ALL). This compound also has potential applications in allergic disorders and autoimmune diseases.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • The Janus kinase (JAK) family regulates critical cellular functions in the lympho-hematopoietic system.
  • JAKs are implicated in cell proliferation, survival, and apoptosis.
  • Elevated JAK expression is observed in pediatric acute lymphoblastic leukemia (ALL).

Purpose of the Study:

  • To evaluate the therapeutic potential of dimethoxyquinazoline compounds targeting JAKs.
  • To investigate the efficacy of WHI-P131 as a selective JAK3 inhibitor for ALL treatment.
  • To explore WHI-P131's broader clinical applications.

Main Methods:

  • Screening of dimethoxyquinazoline compounds for JAK inhibition.
  • Assessing the selectivity of WHI-P131 against JAK1, JAK2, and JAK3.
  • Evaluating the antileukemic properties of WHI-P131 in ALL models.

Main Results:

  • WHI-P131 and WHI-P154 were identified as potent inhibitors of JAK3, with no significant inhibition of JAK1 or JAK2.
  • WHI-P131 demonstrated high potency and selectivity for JAK3.
  • WHI-P131 exhibits antileukemic properties relevant to ALL treatment.

Conclusions:

  • WHI-P131 is a highly selective JAK3 inhibitor with significant therapeutic potential for childhood ALL.
  • WHI-P131 may also be beneficial for treating allergic and autoimmune disorders.
  • Targeting JAK3 represents a promising strategy for novel cancer therapies and immunomodulation.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: